Paper36967374
Prognostic factors after isolated ipsilateral local and regional recurrence in HER2-negative luminal breast cancer: a multi-center retrospective study.
Eom YH and 3 others. World J Surg Oncol, 2023. Cited by 1 paper, by iCite.
Cite this record
ConductScience Library. Prognostic factors after isolated ipsilateral local and regional recurrence in HER2-negative luminal breast cancer: a multi-center retrospective study. Papers, record 36967374. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36967374
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Prognostic factors after isolated ipsilateral local and regional recurrence in HER2-negative luminal breast cancer: a multi-center retrospective study.
- PubMed
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Breast Neoplasms | Major topic |
| Humans | |
| Female | |
| Prognosis | |
| Retrospective Studies | |
| Disease-Free Survival | |
| Neoplasm Recurrence, Local | |
| Erb-b2 Receptor Tyrosine Kinases |
Source PubMed
References31
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 8416714 | Survival of first and second primary breast cancer. | Cancer | 1993 | https://conductscience.org/library/papers/8416714 | PubMed |
| 2 | 25861031 | Survival after locoregional recurrence or second primary breast cancer: impact of the disease-free interval. | PLoS One | 2015 | https://conductscience.org/library/papers/25861031 | PubMed |
| 3 | 29719816 | Local and Regional Breast Cancer Recurrences: Salvage Therapy Options in the New Era of Molecular Subtypes. | Front Oncol | 2018 | https://conductscience.org/library/papers/29719816 | PubMed |
| 4 | 28755621 | Prognostic assessment and systemic treatments of invasive local relapses of hormone receptor-positive breast cancer. | Breast | 2017 | https://conductscience.org/library/papers/28755621 | PubMed |
| 5 | 24439313 | Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial. | Lancet Oncol | 2014 | https://conductscience.org/library/papers/24439313 | PubMed |
| 6 | 21824742 | Prognostic value of breast cancer subtypes on breast cancer specific survival, distant metastases and local relapse rates in conservatively managed early stage breast cancer: a retrospective clinical study. | Eur J Surg Oncol | 2011 | https://conductscience.org/library/papers/21824742 | PubMed |
| 7 | 16859523 | Analysis of incidence and prognostic factors for ipsilateral breast tumour recurrence and its impact on disease-specific survival of women with node-negative breast cancer: a prospective cohort study. | Breast Cancer Res | 2006 | https://conductscience.org/library/papers/16859523 | PubMed |
| 8 | 2198001 | Survival following locoregional recurrence after breast conservation therapy for cancer. | Ann Surg | 1990 | https://conductscience.org/library/papers/2198001 | PubMed |
| 9 | 28109404 | How could breast cancer molecular features contribute to locoregional treatment decision making? | Crit Rev Oncol Hematol | 2017 | https://conductscience.org/library/papers/28109404 | PubMed |
| 10 | 23800672 | Local recurrence following breast-conserving treatment in women aged 40 years or younger: trends in risk and the impact on prognosis in a population-based cohort of 1143 patients. | Eur J Cancer | 2013 | https://conductscience.org/library/papers/23800672 | PubMed |
| 11 | 21900114 | Age, breast cancer subtype approximation, and local recurrence after breast-conserving therapy. | J Clin Oncol | 2011 | https://conductscience.org/library/papers/21900114 | PubMed |
| 12 | 10764430 | Role of isolated locoregional recurrence of breast cancer: results of four prospective studies. | J Clin Oncol | 2000 | https://conductscience.org/library/papers/10764430 | PubMed |
| 13 | 27494111 | Prognostic Impact of Time to Ipsilateral Breast Tumor Recurrence after Breast Conserving Surgery. | PLoS One | 2016 | https://conductscience.org/library/papers/27494111 | PubMed |
| 14 | 16648502 | Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in five National Surgical Adjuvant Breast and Bowel Project node-positive adjuvant breast cancer trials. | J Clin Oncol | 2006 | https://conductscience.org/library/papers/16648502 | PubMed |
| 15 | 19349544 | Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five National Surgical Adjuvant Breast and Bowel Project protocols of node-negative breast cancer. | J Clin Oncol | 2009 | https://conductscience.org/library/papers/19349544 | PubMed |
| 16 | 21523714 | Clinicopathologic factors of the recurrent tumor predict outcome in patients with ipsilateral breast tumor recurrence. | Cancer | 2011 | https://conductscience.org/library/papers/21523714 | PubMed |
| 17 | 1677695 | Significance of ipsilateral breast tumour recurrence after lumpectomy. | Lancet | 1991 | https://conductscience.org/library/papers/1677695 | PubMed |
| 18 | 12393820 | Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. | N Engl J Med | 2002 | https://conductscience.org/library/papers/12393820 | PubMed |
| 19 | 30238274 | Isolated ipsilateral local recurrence of breast cancer: predictive factors and prognostic impact. | Breast Cancer Res Treat | 2019 | https://conductscience.org/library/papers/30238274 | PubMed |
| 20 | 9652841 | Local and distant recurrence after conservative management of "very low-risk" breast cancer are dependent events: a 10-year follow-up. | Int J Radiat Oncol Biol Phys | 1998 | https://conductscience.org/library/papers/9652841 | PubMed |
Cited by1
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1 citation.
| PMID | Title | Journal | Year | In Papers |
|---|---|---|---|---|
| 38727889 | Do we need reshape rTNM staging system for ipsilateral breast tumor recurrence of breast cancer? A population-based, propensity score matched cohort study. | Breast Cancer Res Treat | 2024 | https://conductscience.org/library/papers/38727889 |
Source PubMed
Genes4
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| ERBB2 | 2064 | PubTator's text mining | https://conductscience.org/library/genes/2064 | NCBI Gene |
| ESR1 | 2099 | PubTator's text mining | https://conductscience.org/library/genes/2099 | NCBI Gene |
| NR4A1 | 3164 | PubTator's text mining | https://conductscience.org/library/genes/3164 | NCBI Gene |
| PGR | 5241 | PubTator's text mining | https://conductscience.org/library/genes/5241 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36967374
GET https://conductscience.org/api/papers/v1/36967374/references?page=2